Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2186-2192
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2186
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2186
EUS-CPNvscontrol | After 1 mo (95%CI) | After 3 mo (95%CI) |
Difference in mean % change in pain relief: | ||
No chemo-XRT1 | -59.6% (-95.4 to -27.6)1 | -85.8% (-127.6 to -51.3)1 |
Chemo-XRT | 31.0% (-34.3 to 106.2) | -45.6% (-72.6 to -23.3)1 |
Difference in mean change in MEQ consumption: | ||
No chemo-XRT | -2.4 mg (-58.4 to 60.8) | -144.5 mg (-291 to -30)1 |
Chemo-XRT | 11.4 mg (-23.7 to 39.4) | 26.1 mg (-12.2 to 56.5) |
- Citation: Wyse JM, Chen YI, Sahai AV. Celiac plexus neurolysis in the management of unresectable pancreatic cancer: When and how? World J Gastroenterol 2014; 20(9): 2186-2192
- URL: https://www.wjgnet.com/1007-9327/full/v20/i9/2186.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i9.2186